HIGHLIGHTS
Quercis Pharma is a clinical-stage biotechnology company with Phase 3-ready assets and strong IP extending through 2042.
Nominated for 2025 Galien Award (add logo and call out)
Clinical progress: Phase 3 program for cancer thrombosis prevention under FDA Special Protocol Agreement.
Multiple assets: Cancer-associated thrombosis, Sickle Cell Disease, ALS, COPD, viral diseases.
Strong IP: Patent protection supported by DLA Piper.
Leadership: Our leadership team includes pioneers who have guided the approval of more than 50 therapies. Their collective expertise spans global regulatory strategy, drug development, and commercialization — giving Quercis a foundation few biotech companies can match.
Advisors: Quercis is advised by some of the world’s most accomplished scientists and clinicians, including leaders who have overseen the registration of 17 cancer drugs. With direct ties to Harvard, ETH Zurich, Cornell, and other top institutions, our team brings unmatched experience, credibility, and reach to advance our mission.
Global mission: Committed to responsible pricing and universal access.
Phase 3 readout in cancer thrombosis prevention expected June 2026
Initiation of Phase 3 Sickle Cell Disease Trial
Initiation of Infectious Disease Phase II trials with Administration for Strategic Preparedness and Response (ASPR)
Strategic collaborations to expand development and access.
